Mirabegron is marketed under the brand name Myrbetriq in the United States and as Betmiga in Europe and other regions [1].
Why is Mirabegron also called Myrbetriq or Betmiga?
The different names, Myrbetriq and Betmiga, are brand names used by the pharmaceutical company Astellas Pharma for the same active ingredient, mirabegron [1]. Brand names are chosen by drug manufacturers for marketing purposes and can vary by country due to different regulatory approvals and market strategies.
What is Mirabegron used for?
Mirabegron is a medication used to treat overactive bladder (OAB) with symptoms of urinary urge, urinary frequency, and urge incontinence [1]. It works by relaxing the detrusor muscle in the bladder, which allows the bladder to store more urine and reduces the involuntary contractions that cause the urge to urinate.
How does Mirabegron work?
Mirabegron is a beta-3 adrenergic agonist. It stimulates beta-3 adrenergic receptors in the bladder's detrusor muscle. This stimulation leads to smooth muscle relaxation, increasing bladder capacity and reducing the urgency and frequency of urination associated with overactive bladder [1].
When does Mirabegron's patent expire?
Information regarding the specific patent expiry dates for mirabegron can be found through specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which may include details on when market exclusivity for mirabegron is set to end [2].
What are the potential side effects of Mirabegron?
Common side effects associated with mirabegron may include increased blood pressure, urinary tract infection, headache, and nasopharyngitis (common cold symptoms) [1]. Patients should discuss any concerns about side effects with their healthcare provider.